Genomic analysis of response to bacillus Calmette-Guérin (BCG) treatment in high-grade stage 1 bladder cancer patients

BACKGROUND: Intravesical bacillus Calmette-Guérin (BCG) therapy is standard treatment for high-risk non-muscle invasive bladder cancer (NMIBC) but overall efficacy is low, and no reliable predictive biomarkers currently exist to refine patient selection. We performed genomic analysis on high-grade (...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanders, J. Alexa, Frasier, Connor, Matulay, Justin T., Steuerwald, Nury M., Zhu, Jason, Grigg, Claud M., Kearns, James T., Riggs, Stephen B., Gaston, Kris E., Brouwer, Cory R., Burks, R. Tucker, Hartman, Aaron L., Foureau, David M., Burgess, Earle F., Clark, Peter E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350238/
https://www.ncbi.nlm.nih.gov/pubmed/34430403
http://dx.doi.org/10.21037/tau-21-158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350238/
https://www.ncbi.nlm.nih.gov/pubmed/34430403
http://dx.doi.org/10.21037/tau-21-158

Ejemplares similares